These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Wayne LG; Hayes LG Infect Immun; 1996 Jun; 64(6):2062-9. PubMed ID: 8675308 [TBL] [Abstract][Full Text] [Related]
43. The aerobic activity of metronidazole against anaerobic bacteria. Dione N; Khelaifia S; Lagier JC; Raoult D Int J Antimicrob Agents; 2015 May; 45(5):537-40. PubMed ID: 25813393 [TBL] [Abstract][Full Text] [Related]
44. Dormancy of Mycobacterium tuberculosis and latency of disease. Wayne LG Eur J Clin Microbiol Infect Dis; 1994 Nov; 13(11):908-14. PubMed ID: 7698116 [TBL] [Abstract][Full Text] [Related]
45. Rational Design of Biosafety Level 2-Approved, Multidrug-Resistant Strains of Mycobacterium tuberculosis through Nutrient Auxotrophy. Vilchèze C; Copeland J; Keiser TL; Weisbrod T; Washington J; Jain P; Malek A; Weinrick B; Jacobs WR mBio; 2018 May; 9(3):. PubMed ID: 29844114 [TBL] [Abstract][Full Text] [Related]
46. A Novel Small-Molecule Inhibitor of the Sukheja P; Kumar P; Mittal N; Li SG; Singleton E; Russo R; Perryman AL; Shrestha R; Awasthi D; Husain S; Soteropoulos P; Brukh R; Connell N; Freundlich JS; Alland D mBio; 2017 Feb; 8(1):. PubMed ID: 28196957 [TBL] [Abstract][Full Text] [Related]
47. The effects of exposure time, drug concentration, and temperature on the activity of ethambutol versus Mycobacterium tuberculosis. Gangadharam PR; Pratt PF; Perumal VK; Iseman MD Am Rev Respir Dis; 1990 Jun; 141(6):1478-82. PubMed ID: 2112350 [TBL] [Abstract][Full Text] [Related]
48. [Examination of the antibacterial action of metronidazole against vibrios and Campylobacter (author's transl)]. Füzi M Zentralbl Bakteriol A; 1981; 249(2):242-6. PubMed ID: 7269853 [TBL] [Abstract][Full Text] [Related]
49. The effect of growth rate on pyrazinamide activity in Mycobacterium tuberculosis - insights for early bactericidal activity? Pullan ST; Allnutt JC; Devine R; Hatch KA; Jeeves RE; Hendon-Dunn CL; Marsh PD; Bacon J BMC Infect Dis; 2016 May; 16():205. PubMed ID: 27184366 [TBL] [Abstract][Full Text] [Related]
50. [Critical concentration for definition of rifampicin resistance of tubercle bacilli]. Tsukamura M Kekkaku; 1972 May; 47(5):113-9. PubMed ID: 4625369 [No Abstract] [Full Text] [Related]
51. Drug targets in dormant Mycobacterium tuberculosis: can the conquest against tuberculosis become a reality? Gupta VK; Kumar MM; Singh D; Bisht D; Sharma S Infect Dis (Lond); 2018 Feb; 50(2):81-94. PubMed ID: 28933243 [TBL] [Abstract][Full Text] [Related]
52. Direct detection of rifampin- and isoniazid-resistant Mycobacterium tuberculosis in auramine-rhodamine-positive sputum specimens by real-time PCR. Ruiz M; Torres MJ; Llanos AC; Arroyo A; Palomares JC; Aznar J J Clin Microbiol; 2004 Apr; 42(4):1585-9. PubMed ID: 15071008 [TBL] [Abstract][Full Text] [Related]
53. Detection of rifampin- and ciprofloxacin-resistant Mycobacterium tuberculosis by using species-specific assays for precursor rRNA. Cangelosi GA; Brabant WH; Britschgi TB; Wallis CK Antimicrob Agents Chemother; 1996 Aug; 40(8):1790-5. PubMed ID: 8843282 [TBL] [Abstract][Full Text] [Related]
54. In vitro bactericidal activity of oxazolidinone, RBx 8700 against Mycobacterium tuberculosis and Mycobacterium avium complex. Rao M; Sood R; Malhotra S; Fatma T; Upadhyay DJ; Rattan A J Chemother; 2006 Apr; 18(2):144-50. PubMed ID: 16736882 [TBL] [Abstract][Full Text] [Related]
55. Experimental models to explain the high sterilizing activity of rifampin in the chemotherapy of tuberculosis. Dickinson JM; Mitchison DA Am Rev Respir Dis; 1981 Apr; 123(4 Pt 1):367-71. PubMed ID: 6784622 [TBL] [Abstract][Full Text] [Related]
56. Evaluation of a membrane hybridization array for detection of Mycobacterium tuberculosis complex and resistance to isoniazid and rifampin in sputum specimens, mycobacterial liquid cultures, and clinical isolates. Chen CJ; Yang YC; Huang HH; Chang TC; Lu PL Kaohsiung J Med Sci; 2019 Oct; 35(10):615-623. PubMed ID: 31433118 [TBL] [Abstract][Full Text] [Related]
57. ["In vitro" susceptibility of some aerobic and anaerobic bacteria to three 5-nitro-imidazole derivatives: metronidazole, ornidazole and tinidazole (author's transl)]. Dublanchet A; Durieux R Ann Microbiol (Paris); 1980; 131(1):45-59. PubMed ID: 7362180 [TBL] [Abstract][Full Text] [Related]
58. In vitro bactericidal and in vivo therapeutic activities of a new rifamycin derivative, KRM-1648, against Mycobacterium tuberculosis. Yamamoto T; Amitani R; Suzuki K; Tanaka E; Murayama T; Kuze F Antimicrob Agents Chemother; 1996 Feb; 40(2):426-8. PubMed ID: 8834891 [TBL] [Abstract][Full Text] [Related]
59. Activity of DNA-targeted C8-linked pyrrolobenzodiazepine-heterocyclic polyamide conjugates against aerobically and hypoxically grown Mycobacterium tuberculosis under acidic and neutral conditions. Iacobino A; Giannoni F; Fattorini L; Brucoli F J Antibiot (Tokyo); 2018 Sep; 71(9):831-834. PubMed ID: 29795520 [TBL] [Abstract][Full Text] [Related]